Why Resapp jumped 43% - the FDA story and how it will benefit from Covid-19

The share price of Resapp Health Limited [ASX:RAP], a digital health company developing smartphone applications for the diagnosis and management of respiratory disease has seen some serious upswing this week.

Monday was up 45> on news that Australian telehealth provider and Resapp customer, had completed the initial integration of Resapps technology into the Coviu platform.

Today (Wednesday) it announced it has now launched its bedside sleep apnoea detection app and at the time of writing has gained another 12%>

In my interview earlier this week with with Dr Tony Keating, CEO/Managing Director of Resapp we covered:

• What the Coviu announcement means for Resapp.

• Can Resapp's technology detect COVID-19.

• Why the United States Federal Drug Administration rejected the company's application to sell into USA.

• Would Resapp consider ignoring the USA market altogether.

• What are the chances of Resapp having another competitor in the short term.

• Just how big can the company become.

DISCLAIMER AND IMPORTANT INFORMATION

I own shares in Resapp at the time of writing this post. However I do not accept any payment from this or any other companies I cover. Nor is my interview or blog in any way a recommendation and should not be seen as a form of financial advice. Disruptive technology stocks should be considered very speculative, high-risk, and extremely volatile. There are significant risks inherent in developing new technologies that are not discussed here. You should always seek professional advice before considering any share purchase or sale. Please read our full disclaimer.